CenterBook Partners’s Guardant Health GH Stock Holding History

CenterBook Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,722	Closed	-$264K	–	415
2022 Q4	$264K	Buy	+9,722	New	+$445K	0.04%	348

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CenterBook Partners's GH Position: Q1 2023 in Review

CenterBook Partners sold out of Guardant Health (GH) in Q1 2023, closing a stake of 9,722 shares — an estimated $264K sold.

CenterBook Partners first reported a position in GH in Q4 2022 and held it in 1 quarter. The position peaked at $264K in Q4 2022. 279 funds tracked by Wall St. Rank hold GH as of Q1 2023.

CenterBook Partners reported no remaining Guardant Health position as of Q1 2023 after selling out during the quarter.
CenterBook Partners sold 9,722 Guardant Health shares in Q1 2023, an estimated $264K.
CenterBook Partners first reported a position in Guardant Health in Q4 2022 and held it in 1 quarter.
CenterBook Partners's Guardant Health position peaked at $264K in Q4 2022.
279 funds tracked by Wall St. Rank held Guardant Health as of Q1 2023.

Based on CenterBook Partners's 13F filing for Q1 2023, filed 15 May 2023.